





FIG. 1

Abbreviations: F1=formulation 1 (ie, powder-in-capsule formulation), F2=formulation 2 (i.e., tablet formulation), FE=food effect, MAD=multiple ascending dose, PK=pharmacokinetics, RelBA=relative bioavailability, SAD=single ascending dose.

Part 1 dose levels: 1 mg, 3 mg, 8 mg, 15 mg, 25 mg, and 50 mg powder-in-capsule formulation

Part 2 dose levels: 3 mg, 8 mg, 15 mg, and 25 mg powder-in-capsule formulation

Part 3 dose level: 10 mg powder-in-capsule formulation, 10 mg tablet formulation



Abbreviations: IH=idiopathic hypersomnia, NT1=narcolepsy type 1, NT2=narcolepsy type 2, PK=pharmacokinetics.
Part 4 dose levels: 1 mg, 3 mg, and 8 mg powder-in-capsule formulation
Parts 5 and 6 dose levels: 5 mg, 12 mg, and 25 mg powder-in-capsule formulation
Subjects in Parts 4-6 receive 4 single oral doses separated by 2 days of washout.

FIG. 2




FIG. 3




FIG. 4B




FIG. 4A




FIG. 5




FIG. 6




FIG. 7




FIG. 8




FIG. 9




FIG. 9A




FIG. 10




FIG. 10A




FIG.11




FIG. 11A




FIG. 12





FIG. 13

FIG. 14

Compound A Exhibited CNS Activity in Non-Sleep Deprived Healthy Volunteers

SUBSTITUTE SHEET (RULE 26)






FIG. 15




FIG. 16




FIG. 17




FIG. 18





FIG. 19






Fig. 21